Division of Nephrology, Bone and Mineral Metabolism, Department of Internal Medicine, University of Kentucky, Lexington, KY, USA.
College of Pharmacy, Department of Pharmacy Practice and Science, University of Kentucky, Lexington, KY, USA.
Sci Rep. 2020 Nov 26;10(1):20616. doi: 10.1038/s41598-020-76785-w.
Critically ill patients with requirement of continuous renal replacement therapy (CRRT) represent a growing intensive care unit (ICU) population. Optimal CRRT delivery demands continuous communication between stakeholders, iterative adjustment of therapy, and quality assurance systems. This Quality Improvement (QI) study reports the development, implementation and outcomes of a quality assurance system to support the provision of CRRT in the ICU. This study was carried out at the University of Kentucky Medical Center between September 2016 and June 2019. We implemented a quality assurance system using a step-wise approach based on the (a) assembly of a multidisciplinary team, (b) standardization of the CRRT protocol, (c) creation of electronic CRRT flowsheets, (d) selection, monitoring and reporting of quality metrics of CRRT deliverables, and (e) enhancement of education. We examined 34-month data comprising 1185 adult patients on CRRT (~ 7420 patient-days of CRRT) and tracked selected QI outcomes/metrics of CRRT delivery. As a result of the QI interventions, we increased the number of multidisciplinary experts in the CRRT team and ensured a continuum of education to health care professionals. We maximized to 100% the use of continuous veno-venous hemodiafiltration and doubled the percentage of patients using regional citrate anticoagulation. The delivered CRRT effluent dose (~ 30 ml/kg/h) and the delivered/prescribed effluent dose ratio (~ 0.89) remained stable within the study period. The average filter life increased from 26 to 31 h (p = 0.020), reducing the mean utilization of filters per patient from 3.56 to 2.67 (p = 0.054) despite similar CRRT duration and mortality rates. The number of CRRT access alarms per treatment day was reduced by 43%. The improvement in filter utilization translated into ~ 20,000 USD gross savings in filter cost per 100-patient receiving CRRT. We satisfactorily developed and implemented a quality assurance system for the provision of CRRT in the ICU that enabled sustainable tracking of CRRT deliverables and reduced filter resource utilization at our institution.
危重症患者需要持续肾脏替代治疗 (CRRT),这代表 ICU 患者群体不断扩大。提供最佳 CRRT 治疗需要利益相关者之间持续沟通、反复调整治疗方案以及质量保证体系。本质量改进 (QI) 研究报告了一个质量保证系统的开发、实施和结果,该系统旨在支持 ICU 中 CRRT 的提供。该研究于 2016 年 9 月至 2019 年 6 月在肯塔基大学医学中心进行。我们采用逐步方法实施质量保证系统,基于:(a) 组建多学科团队,(b) 标准化 CRRT 方案,(c) 创建电子 CRRT 流程表,(d) 选择、监测和报告 CRRT 交付的质量指标,以及 (e) 加强教育。我们检查了包含 1185 名接受 CRRT 的成年患者(约 7420 个患者日的 CRRT)的 34 个月数据,并跟踪了 CRRT 交付的选定 QI 结果/指标。通过 QI 干预,我们增加了 CRRT 团队中的多学科专家人数,并确保了医疗保健专业人员的教育连续性。我们将连续静脉-静脉血液透析滤过的使用最大化至 100%,并将使用局部枸橼酸盐抗凝的患者百分比增加了一倍。在研究期间,所提供的 CRRT 流出剂量(30 ml/kg/h)和所提供/规定的流出剂量比(0.89)保持稳定。过滤器寿命从 26 小时增加到 31 小时(p=0.020),尽管 CRRT 持续时间和死亡率相似,但每位患者的平均过滤器利用率从 3.56 个减少到 2.67 个(p=0.054)。每个治疗日的 CRRT 通路报警数量减少了 43%。过滤器利用率的提高使每位接受 CRRT 的 100 名患者的过滤器成本节省了约 2 万美元。我们成功地为 ICU 中 CRRT 的提供开发并实施了质量保证系统,该系统能够可持续地跟踪 CRRT 交付,并减少我们机构的过滤器资源利用。